Figure 1From: Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort studyFlow diagram illustrating cohort selection. Index date refers to the date a new DMARD was initiated. DMARD, disease-modifying antirheumatic drugs; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; HBeAg, hepatitis B e-antigen; HBV DNA, hepatitis B DNA.Back to article page